Hepion (HEPA) Executive Chairman Vincent LoPriore Buys Shares

What Happened Vincent S. LoPriore, Executive Chairman and a director of Hepion Pharmaceuticals (HEPA), reported multiple purchases on 2026-08-03. He acquired a total of 20,000,000 shares: 10,000,000 shares were purchased for cash (8,000,000 @ $0.05 and 2,000,000 @ $0.05) for a total cash outlay of $500,000, and 10,000,000 shares were acquired as derivative instruments with $0.00 reported consideration. All transactions are reported with transaction code P (purchase).

Key Details

• Transaction date: 2026-08-03; Form 4 filed: 2026-08-12 (appears late relative to the 2-business-day Section 16 filing window).
• Prices and amounts: 8,000,000 @ $0.05 ($400,000); 2,000,000 @ $0.05 ($100,000); 8,000,000 @ $0.00 (derivative); 2,000,000 @ $0.00 (derivative). Total shares acquired: 20,000,000; total cash paid: $500,000.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: F1 — LoPriore is Managing Member of Gravitas Capital LP and can vote/dispose securities held by that entity. F2 — LoPriore is trustee and beneficiary of Invictus Capital Advisors Pension Plan and can vote/dispose securities held by that plan. Some reported holdings were through those entities.
• Filing timeliness: Form 4 was filed nine days after the transactions; late Section 16 filings delay public disclosure and can carry regulatory consequences.

Context

• The $0.00 consideration entries are reported as derivative acquisitions; the filing excerpt does not specify the instrument (e.g., conversion, warrant exercise, issuance), only that no cash was paid. That typically means shares were issued/transferred via a derivative mechanism rather than a cash purchase.
• Purchases by insiders can be informative to investors but are not proof of future performance. These filings show meaningful insider buying by the company’s executive chairman, partially via entities he controls.